在肌缩侧面硬化症和与年龄有关的神经退行症中重新审视谷氨酸激发毒性
Frederick J Arnold1,2, Alexandra F Putka2, Urmimala Raychaudhuri1
1Department of Pathology and Laboratory Medicine, University of California Irvine, Irvine, CA 92617, USA.
International journal of molecular sciences
|June 19, 2024
概括
谷氨酸刺激毒性,涉及运动神经元过度兴奋,是肌缩侧面硬化症 (ALS) 的关键机制. 针对这种途径为开发更有效的ALS疗法提供了潜力.
科学领域:
- 神经科学是一个神经科学.
- 神经学 神经学
- 阿尔茨海默病的发病因子
背景情况:
- 肌缩侧面硬化症 (ALS) 是一种进展性运动神经元疾病,治疗选择有限.
- 目前FDA批准的药物对ALS患者提供了适度的益处.
- 了解不同的ALS病因需要确定融合的致病机制.
研究的目的:
- 审查谷氨酸中介激发毒性在ALS病变发生中的作用.
- 阐明导致ALS运动神经元死亡的初级和二级途径.
- 突出刺激毒性作为新型ALS治疗的治疗点.
主要方法:
- 关于ALS病原和谷氨酸激发毒性的科学文献的综述.
- 主要兴奋毒性通路 (突触水平) 的表征.
- 二次兴奋毒性通路的表征 (细胞水平).
主要成果:
- 在ALS中的主要途径包括AMPA受体活性增加,谷氨酸运输受损 (EAAT2功能障碍),谷氨酸释放增强,皮层抑制减少.
- 其次途径涉及线粒体功能障碍,氧化应激和内质网膜应激.
- 这些通路汇聚在一起,导致运动神经元过度兴奋和死亡.
结论:
- 谷氨酸兴奋毒性是肌缩侧面硬化症的一个关键的融合机制.
- 针对激发毒性级联中的关键节点是一个有前途的治疗策略.
- 对刺激毒性途径的进一步研究可能会导致更有效的ALS治疗方法.
相关概念视频
Antiepileptic Drugs: Glutamate Antagonists
319
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
319
Alzheimer's Disease: Overview
462
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
462
Amyloid Fibrils
9.5K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.5K


